Kevan Herold

Summary

Affiliation: Yale University
Country: USA

Publications

  1. pmc Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes
    Kevan C Herold
    Yale University, New Haven, Connecticut, USA
    Diabetes 58:2588-95. 2009
  2. pmc RAGE expression in human T cells: a link between environmental factors and adaptive immune responses
    Eitan M Akirav
    Departments of Immunobiology and Internal Medicine, Yale University, New Haven, Connecticut, United States of America
    PLoS ONE 7:e34698. 2012
  3. doi request reprint Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development
    Nalini K Vudattu
    Yale University, Department of Immunobiology and Internal Medicine, 300 George St, 353E, New Haven, CT 06520, USA 1 203 785 6507
    Expert Opin Biol Ther 14:377-85. 2014
  4. pmc Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges
    Tara Ghazi
    Corresponding author Kevan C Herold
    Diabetes Care 37:210-6. 2014
  5. ncbi request reprint Type 1 diabetes: translating mechanistic observations into effective clinical outcomes
    Kevan C Herold
    Department of Immunobiology, Yale University, New Haven, Connecticut 06520, USA
    Nat Rev Immunol 13:243-56. 2013
  6. pmc Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
    K C Herold
    Departments of Immunobiology and Internal Medicine, Yale University, 300 George St, New Haven, CT 06511, USA
    Diabetologia 56:391-400. 2013
  7. pmc Relapsing and remitting severe hypoglycemia due to a monoclonal anti-insulin antibody heralding a case of multiple myeloma
    F Waldron-Lynch
    Department of Internal Medicine, Section of Endocrinology and Metabolism, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    J Clin Endocrinol Metab 97:4317-23. 2012
  8. pmc Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes
    Kevan C Herold
    Department of Immunobiology, Yale University, New Haven, CT 06511, USA
    J Immunol 187:1998-2005. 2011
  9. pmc Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation
    Vitaly Ablamunits
    Department of Immunobiology and Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
    Diabetes 61:145-54. 2012
  10. pmc Glucose and inflammation control islet vascular density and beta-cell function in NOD mice: control of islet vasculature and vascular endothelial growth factor by glucose
    Eitan M Akirav
    Department of Immunobiology and Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
    Diabetes 60:876-83. 2011

Collaborators

Detail Information

Publications38

  1. pmc Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes
    Kevan C Herold
    Yale University, New Haven, Connecticut, USA
    Diabetes 58:2588-95. 2009
    ..Such assays are vital for monitoring responses to interventions that may modulate disease progression...
  2. pmc RAGE expression in human T cells: a link between environmental factors and adaptive immune responses
    Eitan M Akirav
    Departments of Immunobiology and Internal Medicine, Yale University, New Haven, Connecticut, United States of America
    PLoS ONE 7:e34698. 2012
    ..Our studies have identified the expression of RAGE on adaptive immune cells and a role for this receptor and its ligands in modulating human immune responses...
  3. doi request reprint Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development
    Nalini K Vudattu
    Yale University, Department of Immunobiology and Internal Medicine, 300 George St, 353E, New Haven, CT 06520, USA 1 203 785 6507
    Expert Opin Biol Ther 14:377-85. 2014
    ....
  4. pmc Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges
    Tara Ghazi
    Corresponding author Kevan C Herold
    Diabetes Care 37:210-6. 2014
    ..GLP-1 analogs may be useful as an adjunctive treatment in type 1 diabetes. ..
  5. ncbi request reprint Type 1 diabetes: translating mechanistic observations into effective clinical outcomes
    Kevan C Herold
    Department of Immunobiology, Yale University, New Haven, Connecticut 06520, USA
    Nat Rev Immunol 13:243-56. 2013
    ....
  6. pmc Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
    K C Herold
    Departments of Immunobiology and Internal Medicine, Yale University, 300 George St, New Haven, CT 06511, USA
    Diabetologia 56:391-400. 2013
    ..We tested whether treatment with teplizumab (a Fc receptor non-binding anti-CD3 monoclonal antibody), after the new-onset period, affects the decline in C-peptide production in individuals with type 1 diabetes...
  7. pmc Relapsing and remitting severe hypoglycemia due to a monoclonal anti-insulin antibody heralding a case of multiple myeloma
    F Waldron-Lynch
    Department of Internal Medicine, Section of Endocrinology and Metabolism, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    J Clin Endocrinol Metab 97:4317-23. 2012
    ..We report a novel case of insulin autoimmune syndrome (IAS) presenting with hypoglycemia due to production of a monoclonal anti-insulin antibody in a patient subsequently found to have multiple myeloma (MM)...
  8. pmc Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes
    Kevan C Herold
    Department of Immunobiology, Yale University, New Haven, CT 06511, USA
    J Immunol 187:1998-2005. 2011
    ..We conclude that in patients with type 1 diabetes mellitus, anti-B cell mAb causes increased proliferative responses to diabetes Ags and attenuated β-cell loss. The way in which these responses affect the disease course remains unknown...
  9. pmc Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation
    Vitaly Ablamunits
    Department of Immunobiology and Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
    Diabetes 61:145-54. 2012
    ..These studies indicate that the combination of anti-CD3 mAb with IL-1RA is synergistic in reversal of diabetes through a combination of mechanisms. The combination causes persistent remission from islet inflammation...
  10. pmc Glucose and inflammation control islet vascular density and beta-cell function in NOD mice: control of islet vasculature and vascular endothelial growth factor by glucose
    Eitan M Akirav
    Department of Immunobiology and Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
    Diabetes 60:876-83. 2011
    ..Our objective was to study the effects of glucose and inflammation on islet vascularity and on β function, mass, and insulin in immunologically tolerant anti-CD3 monoclonal antibody (mAb)-treated and prediabetic NOD mice...
  11. doi request reprint Human regulatory CD8 T cells
    Vitaly Ablamunits
    Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA
    Ann N Y Acad Sci 1150:234-8. 2008
    ....
  12. ncbi request reprint A patient with type B insulin resistance syndrome, responsive to immune therapy
    Kathleen A Page
    Section of Endocrinology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06520 8020, USA
    Nat Clin Pract Endocrinol Metab 3:835-40. 2007
    ..She remained hyperglycemic (blood glucose levels 16.7-27.8 mmol/l), despite intravenous insulin at doses as high as 30,000 U/day...
  13. doi request reprint Anti-CD3 mAbs for treatment of type 1 diabetes
    Adam Kaufman
    Department of Immunobiology, Yale University, New Haven, CT 06520, USA
    Diabetes Metab Res Rev 25:302-6. 2009
    ..However, these agents alone do not restore normal glucose control, and future approaches will likely require combinations of agents with complementary immune or metabolic activity...
  14. pmc Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF
    Vitaly Ablamunits
    Departments of Immunobiology and Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
    Eur J Immunol 40:2891-901. 2010
    ..These studies have identified a novel mechanism of immune regulation by anti-CD3 mAb and markers that may be used to track inducible CD8(+) Treg in settings such as chronic inflammation or immune therapy...
  15. pmc Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years
    Kevan C Herold
    Department of Immunobiology, Yale University, New Haven, CT 06520, USA
    Clin Immunol 132:166-73. 2009
    ..The drug may marginate rather than deplete T cells. C-peptide levels may remain detectable up to 5 years after treatment...
  16. pmc RAGE ligation affects T cell activation and controls T cell differentiation
    Yali Chen
    Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA
    J Immunol 181:4272-8. 2008
    ..We conclude that activation of RAGE on T cells is involved in early events that lead to differentiation of Th1(+) T cells...
  17. ncbi request reprint Autoimmunity and beta cell regeneration in mouse and human type 1 diabetes: the peace is not enough
    Vitaly Ablamunits
    Section of Immunobiology, Department of Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
    Ann N Y Acad Sci 1103:19-32. 2007
    ..Additional therapeutic modalities capable of stimulating beta cell regeneration in the absence of active autoimmune destruction are urgently needed...
  18. ncbi request reprint Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress
    Kevan Herold
    Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
    J Leukoc Biol 82:204-12. 2007
    ..Identification of the threshold beyond which ligands of RAGE mediate repair versus injury is a central component in delineating optimal strategies to target RAGE in the clinic...
  19. pmc Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies
    Simona Cernea
    Department of Immunobiology, Yale University, 10 Amistad Street, 131D, New Haven, CT 06520, USA
    Clin Immunol 134:121-9. 2010
    ..The frequency of certain specificities increases after treatment with anti-CD3 mAb. Their modulated phenotype may have functional consequences for their pathogenicity...
  20. doi request reprint Prevention of type 1 diabetes: the time has come
    Jennifer Sherr
    Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA
    Nat Clin Pract Endocrinol Metab 4:334-43. 2008
    ..In this Review we discuss risk-stratification techniques and how they are applied, other diagnostic criteria, and outcomes from diabetes-prevention trials...
  21. ncbi request reprint Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells
    Nicole A Sherry
    Department of Immunobiology, Yale University, New Haven, CT 06520, USA
    Endocrinology 148:5136-44. 2007
    ..This combinatorial approach may be useful in treatment of patients with new-onset T1DM...
  22. pmc Promotion of beta-cell differentiation in pancreatic precursor cells by adult islet cells
    Wei Chen
    Department of Immunobiology and Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
    Endocrinology 150:570-9. 2009
    ..We conclude that mature beta-cells can modify the differentiation of precursor cells and suggest a mechanism whereby changes in differentiation of beta-cells can be affected by other beta-cells...
  23. ncbi request reprint Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes
    Nicole A Sherry
    Section of Immunobiology, Yale University, 300 Cedar St, Room S155B, New Haven, CT 06520, USA
    Diabetes 55:3238-45. 2006
    ..Correction of the beta-cell loss in type 1 diabetes will, therefore, require strategies that target both the immunologic and cellular mechanisms that destroy and maintain beta-cell mass...
  24. doi request reprint Advances in Type 1 diabetes therapeutics: immunomodulation and beta-cell salvage
    Frank Waldron-Lynch
    Department of Immunobiology, Yale University, New Haven, CT 06520, USA
    Endocrinol Metab Clin North Am 38:303-17, viii. 2009
    ..Agents that augment recovery of dysfunctional beta-cells, and other compounds that may be able to induce beta-cell replication, are logical additions once immune tolerance is achieved...
  25. pmc Beta-cell mass and type 1 diabetes: going, going, gone?
    Eitan Akirav
    Department of Immunobiology, Yale University, New Haven, Connecticut, USA
    Diabetes 57:2883-8. 2008
    ..Our objective is to review newer human and animal studies of beta-cell destruction and regeneration and consider the implications for treatment of type 1 diabetes...
  26. doi request reprint Generation and function of human regulatory CD8+ T cells induced by a humanized OKT3 monoclonal antibody hOKT3gamma1 (Ala-Ala)
    Vitaly Ablamunits
    Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA
    Hum Immunol 69:732-6. 2008
    ..We compare our data on CD8+ regulatory cells induced by anti-CD3 stimulation with those reported in other experimental systems to identify both common and unique features of these cells...
  27. ncbi request reprint Treatment of Type 1 diabetes with anti-CD3 monoclonal antibody: induction of immune regulation?
    Kevan C Herold
    Department of Medicine, the Naomi Berrie Diabetes Center, and the Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    Immunol Res 28:141-50. 2003
    ..The induction of cells with a regulatory phenotype may account for the ability of anti-CD3 MAb to induce immune regulation...
  28. ncbi request reprint Insulin secretion in type 1 diabetes
    Chynna Steele
    Department of Medicine, Division of Endocrinology, and the Naomi Berrie Diabetes Center, College of Physicians and Surgeons, Columbia University, New York, New York, USA
    Diabetes 53:426-33. 2004
    ....
  29. ncbi request reprint Treatment of type 1 diabetes mellitus to preserve insulin secretion
    Kevan C Herold
    Division of Endocrinology, Department of Medicine, Naomi Berrie Diabetes Center, College of Physicians and Surgeons, Columbia University, 1150 St Nicholas Avenue, New York, NY 10032, USA
    Endocrinol Metab Clin North Am 33:93-111, ix. 2004
  30. ncbi request reprint Continuous subcutaneous insulin infusion in older patients with type 1 diabetes
    Leigh Siegel-Czarkowski
    Diabetes Care 27:3022-3. 2004
  31. ncbi request reprint Use of anti-CD3 monoclonal antibody to induce immune regulation in type 1 diabetes
    Brygida C Bisikirska
    Department of Medicine, PH 10 105, 630 W 168th Street, New York, NY 10032, USA
    Ann N Y Acad Sci 1037:1-9. 2004
    ..These initial studies have shown clinical efficacy of treatment with anti-CD3 mAb and suggest a novel mechanism that may account for the lasting effects of treatment...
  32. ncbi request reprint A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes
    Kevan C Herold
    Associate Professor of Medicine, Columbia University, PH10 105, 630 W 168th St, New York, NY 10032, USA
    Diabetes 54:1763-9. 2005
    ....
  33. ncbi request reprint Natural history of beta-cell function in type 1 diabetes
    Nicole A Sherry
    Naomie Berrie Diabetes Center and Department of Pediatrics, College of Physicians and Surgeons, Columbia University, 1150 St Nicholas Ave, New York, New York 10032, USA
    Diabetes 54:S32-9. 2005
    ..Understanding the modifiers and predictors of beta-cell function would allow targeting immunological approaches to those individuals most likely to benefit from therapy...
  34. ncbi request reprint Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, PO Box 016960 D110, Miami, FL 33101, USA
    Diabetes Care 29:643-9. 2006
    ..The goal of this study was to utilize data from the Diabetes Prevention Trial-Type 1 (DPT-1) to obtain a picture of the metabolic progression to type 1 diabetes over a period of approximately 2.5 years before its diagnosis...
  35. ncbi request reprint Drug insight: New immunomodulatory therapies in type 1 diabetes
    Simona Cernea
    Columbia University, New York, NY, USA
    Nat Clin Pract Endocrinol Metab 2:89-98. 2006
    ..Ultimately, preservation and even improvement in beta-cell mass is the goal of therapy. The means needed to achieve this will depend on the timing and mechanisms of the immune intervention and might require combinations of agents...
  36. ncbi request reprint Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study
    Vicki Seyfert-Margolis
    Immune Teolerance Network, Bethesda, Maryland, USA
    Diabetes 55:2588-94. 2006
    ..They may be useful for assessment of cellular autoimmune responses involved in type 1 diabetes...
  37. ncbi request reprint Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, P O Box 016960 D110, Miami, FL 33101, USA
    Diabetes Care 30:38-42. 2007
    ....
  38. ncbi request reprint Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
    Kevan C Herold
    Naomi Berrie Diabetes Center and the Department of Medicine, Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York 10032, USA
    N Engl J Med 346:1692-8. 2002
    ..Preclinical studies suggested that a monoclonal antibody against CD3 could reverse hyperglycemia at presentation and induce tolerance to recurrent disease...

Research Grants18

  1. Phase II Trial of HOKT3gamma 1 (ALA-ALA) in Type 1 Diabetes
    Kevan C Herold; Fiscal Year: 2010
    ..Thus, this proposal will bridge both mechanistic studies and a clinical trial to develop a new treatment paradigm that may be beneficial to a large number of patients with T1DM. ..
  2. PHASE I/II TRIAL OF HOKT3(1(ALA-ALA) IN TYPE 1 DIABETES
    Kevan Herold; Fiscal Year: 2004
    ..As a result of these studies, future studies will be of broader scope with a focus on clinical efficacy of non-FcR binding anti-CD3 therapy. ..
  3. PHASE I/II TRIAL OF HOKT3(1(ALA-ALA) IN TYPE 1 DIABETES
    Kevan Herold; Fiscal Year: 2000
    ..As a result of these studies, future studies will be of broader scope with a focus on clinical efficacy of non-FcR binding anti-CD3 therapy. ..
  4. Phase II Trial of HOKT3gamma 1 (ALA-ALA) in Type 1 Diabetes
    Kevan Herold; Fiscal Year: 2009
    ..Thus, this proposal will bridge both mechanistic studies and a clinical trial to develop a new treatment paradigm that may be beneficial to a large number of patients with T1DM. ..
  5. Phase II Trial of HOKT3gamma 1 (ALA-ALA) in Type 1 Diabetes
    Kevan Herold; Fiscal Year: 2009
    ..Thus, this proposal will bridge both mechanistic studies and a clinical trial to develop a new treatment paradigm that may be beneficial to a large number of patients with T1DM. ..
  6. Islet growth in NOD mice tolerant to autoimmune diabetes
    Kevan Herold; Fiscal Year: 2005
    ..The proposal will develop a partnership between Dr. Kevan Herold, whose work has been in the immunology and immunotherapy of Type 1 diabetes and Dr...
  7. Type 1 Diabetes TrialNet: Clinical Center at Columbia University
    Kevan Herold; Fiscal Year: 2007
    ..The Center will be able to coordinate with other centers in carrying out future trials of TrialNet. ..
  8. Phase II Trial of HOKT3gamma 1 (ALA-ALA) in Type 1 Diabetes
    Kevan Herold; Fiscal Year: 2007
    ..Thus, this proposal will bridge both mechanistic studies and a clinical trial to develop a new treatment paradigm that may be beneficial to a large number of patients with T1DM. ..
  9. Phase II Trial of HOKT3gamma 1 (ALA-ALA) in Type 1 Diabetes
    Kevan Herold; Fiscal Year: 2006
    ..Thus, this proposal will bridge both mechanistic studies and a clinical trial to develop a new treatment paradigm that may be beneficial to a large number of patients with T1DM. ..
  10. Phase II Trial of HOKT3gamma 1 (ALA-ALA) in IDDM
    Kevan Herold; Fiscal Year: 2005
    ..Thus, this proposal will bridge both mechanistic studies and a clinical trial to develop a new treatment paradigm that may be beneficial to a large number of patients with T1DM. ..
  11. Combination of Anti-CD3 and Ag-Specific Immunotherapy
    Kevan Herold; Fiscal Year: 2005
    ..Furthermore, we propose that this effect of the combinatorial approach will allow us to maintain the clinical benefits by repeated administration of antigen. ..
  12. Islet growth in NOD mice tolerant to autoimmune diabetes
    Kevan Herold; Fiscal Year: 2005
    ..The proposal will develop a partnership between Dr. Kevan Herold, whose work has been in the immunology and immunotherapy of Type 1 diabetes and Dr...
  13. Islet growth in NOD mice tolerant to autoimmune diabetes
    Kevan Herold; Fiscal Year: 2004
    ..The proposal will develop a partnership between Dr. Kevan Herold, whose work has been in the immunology and immunotherapy of Type 1 diabetes and Dr...
  14. PHASE I/II TRIAL OF HOKT3(1(ALA-ALA) IN TYPE 1 DIABETES
    Kevan Herold; Fiscal Year: 2002
    ..As a result of these studies, future studies will be of broader scope with a focus on clinical efficacy of non-FcR binding anti-CD3 therapy. ..
  15. PHASE I/II TRIAL OF HOKT3(1(ALA-ALA) IN TYPE 1 DIABETES
    Kevan Herold; Fiscal Year: 2003
    ..As a result of these studies, future studies will be of broader scope with a focus on clinical efficacy of non-FcR binding anti-CD3 therapy. ..
  16. PHASE I/II TRIAL OF HOKT3(1(ALA-ALA) IN TYPE 1 DIABETES
    Kevan Herold; Fiscal Year: 2002
    ..As a result of these studies, future studies will be of broader scope with a focus on clinical efficacy of non-FcR binding anti-CD3 therapy. ..
  17. PHASE I/II TRIAL OF HOKT3(1(ALA-ALA) IN TYPE 1 DIABETES
    Kevan Herold; Fiscal Year: 2001
    ..As a result of these studies, future studies will be of broader scope with a focus on clinical efficacy of non-FcR binding anti-CD3 therapy. ..